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The inducible inflammatory enzyme cyclooxygenase-2 (COX-2) and its product 
prostaglandin E2 (PGE2) are prominent tumour promoters, and expression of COX-2 is 
elevated in a number of tumours of both humans and canines. Targeting COX-2 in cancer is 
an attractive option due to readily available non-steroidal anti-inflammatory drugs (NSAIDs), 
and there is a clear epidemiological link between NSAID use and cancer risk. In this study 
we aim to establish the anti-tumourigenic effects of the selective, long-acting COX-2 
inhibitor mavacoxib. We demonstrate here that mavacoxib is cytotoxic to a panel of human 
and canine osteosarcoma, mammary and bladder carcinoma cancer cell lines; that it can 
induce apoptosis and inhibit the migration of these cells. Interestingly, we establish that 
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mavacoxib can exert these effects independently of elevated COX-2 expression. This study 
highlights the potentially novel use of mavacoxib as a cancer therapeutic, suggesting that 
mavacoxib may be an effective anti-cancer agent independent of tumour COX-2 expression.  
 




The cyclooxygenase (COX) enzymes (COX-1 and COX-2) are key in the synthesis of 
prostaglandins, prostacyclin and thromboxane from arachidonic acid. COX-2 is an inducible 
enzyme stimulated as part of an immune response by inflammatory cytokines and growth 
factors, and produces inflammatory prostaglandins involved in pain signalling and swelling 
1
. 
In cancer, COX-2 is overexpressed with adverse consequences; tumours with elevated COX-
2 levels are more aggressive, with increased incidence of metastasis and resistance to 
therapeutics.  Many cancer types (both human and canine) have increased expression of 








 and bone cancer 
10–13
. The COX-2 / 
prostaglandin axis targets many downstream factors that play important roles in tumourigenic 
pathways. Prostaglandins, particularly PGE2, are involved in enhancing tumour growth and 
progression through increasing cancer cell proliferation 
11,14
, increasing the metastatic and 
invasive potential of cancer cells via increased mobility 
15,16
 and enhancing angiogenesis via 
stimulation of vascular endothelial growth factor (VEGF) 
17
. PGE2 signalling mechanisms are 
also involved in the ability of cancer cells to evade apoptosis. This occurs due to the 
deregulation of apoptotic proteins via the loss, damage or inhibition of the tumour suppressor 
protein p53, and by increasing the expression of anti-apoptotic proteins and reducing the 
expression of pro-apoptotic proteins 
15
. The ability to avoid controlled cell death allows 
damaged cancer cells to grow rapidly to form an aggressive tumour.  











Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX enzymes, and coxibs 
are a family of NSAIDs which selectively target COX-2. The use of NSAIDs to treat 
inflammatory conditions such as arthritis is universally accepted. Experimentally, both 
NSAIDs and coxibs have been shown to inhibit tumorigenesis 
8,18–20
 by inhibiting cancer cell 
growth and proliferation 
14,21
, modulating apoptotic activity 
22–24
, reducing the metastatic and 
invasive potential of cells 
16,25,26
 and by inhibiting angiogenesis 
27–29
. Positive results from 
pre-clinical and clinical trials in which coxibs have been used as a preventative agent or as a 
therapeutic in combination with either chemotherapeutics or surgery demonstrates the 
potential of using such drugs as cancer therapeutics 
17,30–33
. In veterinary medicine mavacoxib 
(Trocoxil) is of interest because it is currently licensed to treat pain and inflammation 
associated with canine osteoarthritis where long term (up to 6 months) treatment is required 
34
. Mavacoxib is unique in the family of NSAIDs and coxibs as it exhibits a low clearance 
rate, a relatively large distribution volume and a long plasma half-life, resulting in a reduced 
dosing regimen. Consequently, the potential clinical benefit of using mavacoxib is high.  
 
There is limited research into the potential anti-cancer effects of mavacoxib. We have 
previously shown that mavacoxib exhibits anti-proliferative and pro-apoptotic effects in a 
panel of canine cancer cell lines and cancer stem cells in-vitro 
35,36
. Here, we investigate the 
effects of mavacoxib on a panel of canine and human cancer cell lines. The cancers studied 
include osteosarcoma, mammary carcinoma and transitional cell carcinoma (TCC) of the 
urinary bladder, which exhibit cross species similarities. COX-2 has an important role in 
disease progression in these cancer types and in both species the use of NSAIDs has shown 
positive therapeutic effects 
2,4-5,11,20,35,37–48
. We aim to determine if mavacoxib is directly 
cytotoxic to, and is able to inhibit the migration of these particular cell lines. We aim to begin 










to establish not only if mavacoxib has potential as an anti-cancer agent against these cancer 
types, but also if this response is comparable between species. 
Materials and methods 
Cell culture 
 
The canine osteosarcoma cell lines, KTOSA5 
35
 and CSKOS 
49
 (gifted from Chand 
Khanna (NIH)) were maintained in Dulbecco‟s modified Eagle‟s medium (DMEM) 
(ThermoFisher Scientific, Massachusetts, USA). The human osteosarcoma cell line U2OS 
was grown in McCoys 5A modified medium (ThermoFisher Scientific). Canine mammary 
carcinoma cells REM134 (REM) 
50
 were maintained in DMEM. Canine inflammatory 
mammary carcinoma cells LILY (gifted from Dr De Maria Raffaella, University of Turin) 
were grown in RPMI medium 1640 (ThermoFisher Scientific) supplemented with 10 μg/mL 
human insulin (Sigma-Aldrich, Missouri, USA) and 10 ng/mL human recombinant EGF 
(Peprotech, London, UK). Canine transitional cell carcinoma of the urinary bladder cell lines 
K9TCC, K9TCC-AXA, K9TCC-In and K9TCC-Sh (gifted from Deborah Knapp and Jane 
Stewart (Purdue University)) were maintained in DMEM/F-12 (ThermoFisher Scientific) 
containing HEPES and L-glutamine. Human transitional cell carcinoma of the urinary 
bladder cell lines T24, 5637 and HT-1376 cells were gifted from Anne Kiltie (Oxford 
University). The T24 cell line were maintained in McCoy‟s 5A (modified) medium, 5637 cell 
line were maintained in RPMI-1640 medium (ATCC modification) (ThermoFisher Scientific) 
and the HT-1376 cell line were maintained in Advanced MEM (minimum essential medium) 
(ThermoFisher Scientific) supplemented with 1% glutamine. All cell culture medium was 
supplemented with 10% fetal bovine serum (FBS) and 100 μg/mL penicillin/streptomycin 
(ThermoFisher Scientific) and were maintained at 37°C in a humidified 5 % CO2 incubator.  
 














, Zoetis, London, UK) was dissolved in DMSO and diluted in 
media immediately before use. Vehicle controls were included in all experiments.  
 




 Luminescent Cell Viability Assay (Promega, Madison, WI, USA) 
was used according the manufacturer‟s instructions. Briefly, 500 cells per well were seeded 
in a 96-well plate in triplicate. Cells were incubated for 24 hours at 37
o
C, 5% CO2. Serial 
dilutions of mavacoxib (0 – 200 M) were added and cell viability was assayed after 72 
hours. Luminescence was recorded by a spectrophotometer (WPA Biowave, Biochrom, 
Cambridge, UK) using the Viktor3 software (PerkinElmer, Massachusetts, USA). Data was 
averaged and normalized against the average signal of vehicle control treated samples and a 
dose-response curve was produced. The IC50 for each cell line treated with mavacoxib was 
calculated using GraphPad Prism version 7.0c for Mac OS X (GraphPad software, CA USA) 
using the log(inhibitor) vs response variable slope equation. 
 
Colony formation assay 
 
Cells were seeded as single cells at low density (250 cells / 10 cm plate for CSKOS, 
REM, K9TCC, K9TCC-AXA, K9TCC-In, K9TCC-Sh cells and 100 cells / 10 cm plate for 
KTOSA5 cells) and treated with 0, 25, 50 or 75 M mavacoxib while still in suspension. 
Plates were incubated at 37°C in humidified 5% CO2 incubator for 10-14 days. Cell culture 
media was changed once a week. Colonies were fixed by incubating with methanol for 5 










minutes at room temperature and stained with Giemsa stain at 1:20 dilution (ThermoFisher 
Scientific). For each concentration tested, plates were set up in triplicate or quadruplicate. 
The total number of colonies was manually counted and the average number of colonies for 
each condition calculated.  
 
Cellular migration assay 
 
Scratch assay. Cells were grown until 80-90% confluent in 10 cm plates. The cell culture 
media was replaced and plates were treated with 0 – 125 M mavacoxib and incubated at 
37°C in humidified 5% CO2 incubator overnight. A scratch was made in the confluent 
monolayer of cells down the centre of each plate with a pipette tip.  
 
Migration assay. Cells were seeded at 3 x 10
5 
cells / well of the cell culture insert in a 
volume of 70 μl cell culture medium. Plates were incubated for 24 hours at 37°C, 5% CO2. 
Once confluent, cell culture medium was removed from each well and replaced with new cell 
culture medium containing 0 – 125 M mavacoxib and incubated at 37°C, 5% CO2 for 24 
hours. After 24 hours incubation each insert was removed from its well. One ml of cell 
culture medium was added to each well.  
 
In both assays the width of the gap was measured at 6 points using the Axiovert 40 CFL 
microscope coupled with an AxioCAM HRm camera (Carl Zeiss Ltd, Cambridge, UK) and 
an average taken. Measurements were made at 0, 4, 8, 24, 28, 32 and 48 hours. Scratch width 
was converted to „relative migration distance‟ of cells, where the distance is a percentage of 
the initial wound width at 0 hours.  
 












Apoptotic activity was measured using the Caspase-Glo
®
 3-7 Assay (Promega) 
according to the manufacturer‟s instruction. Briefly, cells were seeded at 500 cells per well in 
96-well plates and incubated for 24 hours at 37
o
C, 5% CO2. Serial dilutions of mavacoxib (0 
– 200 M) were added to appropriate wells. Apoptotic activity was measured 48 hours post-
treatment. Luminescence was recorded by a spectrophotometer (WPA Biowave, Biochrom) 
using the Viktor3 software (PerkinElmer). Luminescence is proportional to the amount of 
caspase activity present. Data was averaged and normalized against the average signal of 




The Canine Prostaglandin E2 ELISA Kit from BlueGene (AMS Biotechnology, 
Abingdon, UK) was used to determine the amount of PGE2 exported from the cells into the 
cell culture media. Cells were seeded in equal numbers using the relevant cell culture media 
which was replaced with fresh cell culture media when the cells reached 50% confluency. 
After 24 hours incubation the cell culture media was removed from each flask, centrifuged 
and the ELISA carried out following the manufacturer‟s protocol. Optical density of the 
samples was measured at 450 nm using the spectrophotometer (WPA Biowave, Biochrom) 
with Viktor3 software (PerkinElmer). A standard curve was produced by plotting the 
standards (a linear relationship was determined) and the equation of the line was used to 
calculate the concentration of the samples. 
 










Western blot analysis 
 
Cells were treated with 0, 25, 50 or 75 M mavacoxib for 24 hours prior to harvesting 
for western blot analysis. Cells were harvested and cell pellets were lysed with urea lysis 
buffer (7 M urea, 0.1 M DTT, 0.05% Triton X-100, 25 mM NaCl, 20 mM Hepes pH 7.5). A 
Bradford assay was used to quantify protein concentrations of samples prior to all western 
blotting using Quick Start™ Bradford 1x Dye Reagent (Bio-Rad Laboratories, California, 
USA). Equal amounts of protein (30 g) were resolved based on their molecular weight by 
SDS polyacrylamide gel electrophoresis (SDS PAGE) 
51





 nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK) and 
hybridised to an appropriate primary antibody and HRP-conjugated secondary antibody for 





Pharmacia Biotech).  
 
The following primary antibodies were utilized to assess protein expression: COX-2 
(C-terminus of COX-2 of human origin, sc-1745) from Santa Cruz Biotechnology (Texas, 
USA); ERK1/2 (p44/42 MAPK (137F5)), phosphorylated-ERK1/2 (phospho-p44/42 MARK, 
dually phosphorylated at Thr202/Tyr204), Akt (Akt1, Akt2 and Akt3), phosphorylated-Akt 
(Akt1 phosphorylated at Ser473, and Akt2 and Akt3 when phosphorylated at corresponding 
residues) all from Cell Signalling Technology (Massachusetts, USA); and β-actin (N-terminal 
of the beta isoform of actin, ab6276) from Abcam (Cambridge, UK). Secondary antibodies 
were HRP-conjugated swine anti-rabbit IgG, rabbit anti-mouse IgG and rabbit anti-goat IgG 
from Dako, Agilent Technologies (CA, USA). 













Data were expressed as mean  SD. Statistical analysis of student‟s t-test or Mann-
Whitney test were performed using Minitab® statistical software (PA, USA). Spearman‟s 
correlation for nonparametric analysis was performed using GraphPad Prism version 7.0c for 
Mac OS X (GraphPad software, CA USA). Differences were deemed significant with a p-




Characterization of COX-2 expression and PGE2 production in a panel of canine and 
human cancer cell lines 
 
A panel of canine and human cancer cell lines were characterised by cellular 
morphology and doubling time (Supplementary table 1). We showed a spectrum of 
morphology from classic cobblestone morphology associated with epithelial cells (for 
example, the mammary carcinoma cell line REM and the human bladder transitional cell 
carcinoma cell lines K9TCC, K9TCC-AXA, K9TCC-In and K9TCC-Sh) and elongated 
protrusions associated with mesenchymal cells (for example, the canine osteosarcoma cell 
lines CSKOS and KTOSA5 and the inflammatory mammary carcinoma cell line LILY). 
There was also a range in doubling time from 7.0 (T24 cells) to 10.6 hours (K9TCC-In cells) 
(Supplementary table 1).  
 










The expression of COX-2 protein in each cell line was determined by western blotting 
(Figure 1A). COX-2 expression was negligible in U2OS (human osteosarcoma), CSKOS 
(canine osteosarcoma) and T24 (human bladder TCC) cell lines, whereas low level COX-2 
expression was detected in KTOSA5 (canine osteosarcoma), LILY (canine inflammatory 
mammary carcinoma) and HT-1376 (human bladder TCC) cell lines and high COX-2 
expression was detected in REM (canine mammary carcinoma), 5637 (human osteosarcoma) 
and in K9TCC, K9TCC-AXA, K9TCC-In and K9TCC-Sh (canine bladder TCC cell lines). 
COX-2 expression was quantified from western blot analysis relative to -actin for each cell 
line and this data is displayed in Table 1. One of the main products of the COX-2 enzyme 
reaction is PGE2 and we confirmed the amount of PGE2 produced by each cell line by ELISA 
(Table 1). We show that bladder TCC cell lines produce more PGE2 than the osteosarcoma 
and mammary carcinoma cell lines (Table 1). To determine if there is a correlation between 
PGE2 production and COX-2 expression we utilized the Spearman‟s statistical test due to the 
nonparametric nature of the data. Here, we confirmed that COX-2 expression and PGE2 
production are positively correlated (r=0.7478, Figure 1B) and that this correlation is 
statistically significant (p=0.0071).  
 
Mavacoxib is cytotoxic to human and canine cancer cell lines and induces replicative 
cell death  
 
To determine if mavacoxib is cytotoxic to cancer cells we treated a panel of cancer 
cell lines with increasing doses of mavacoxib and assessed cell viability 72 hours after 
treatment. We showed that cell viability was reduced in a dose-dependent manner by 
mavacoxib in all cell lines tested indicating that mavacoxib is cytotoxic (Figure 2Ai-v. Data 
shown is representative of all cell lines). However, sensitivity to mavacoxib varied between 










the cell lines, with IC50 values ranging from 34.5 M (K9TCC-AXA) to 157.7 M (HT-
1376) (Table 2). To determine if there is a correlation between COX-2 expression and 
sensitivity to mavacoxib, Spearman‟s statistical test was used to assess correlation between 
IC50 values and COX-2 expression. There was no statistically significant correlation between 
these factors (r = -0.2222, p = 0.4839), suggesting that mavacoxib may be an effective 
cytotoxic agent against these cell types, including those with low COX-2 expression.  
 
To elucidate the downstream signalling pathways involved in cell survival that may 
be affected by mavacoxib we treated cells with increasing doses of mavacoxib for 24 hours 
and probed for ERK, phosphorylated-ERK (p-ERK), Akt and phosphorylated-Akt (p-Akt) 
(Figure 2B. representative data shown). COX-2 is known to activate the MAPK/ERK and 
PI3K/Akt pathways by the action of PGE2 via EP2/EP4 receptors 
52–54
. Dual phosphorylation 
of both ERK and Akt is required for activation, which both then go on to phosphorylate 
numerous transcription factors downstream that are involved in promoting cell growth and 
cell cycle progression. Several studies have demonstrated that COX-2 inhibitors induce 
apoptosis and reduce cell proliferation and survival via the ERK and Akt pathways 
55,56
. The 
response of these pathways to increasing doses of mavacoxib in the cell lines tested here was 
variable. In CSKOS cells, p-Akt was downregulated with increasing does of mavacoxib, as 
was total Akt in U2OS cells. In REM cells both p-ERK and p-Akt were increased in 
expression with increasing doses of mavacoxib, and in K9TCC cells p-ERK expression was 
also increased with mavacoxib treatment. This result suggests that mavacoxib may inhibit the 
Akt pathway in canine osteosarcoma cell lines (CSKOS and U2OS) to reduce cell viability. 
Interestingly, other studies have noted that the activation of the ERK pathway, which is 
usually associated with enhancing cell proliferation and survival, can induce anti-proliferative 
effects and that this can occur with the use of COX-2 inhibitors 
24,57,58
. Further investigation 










into these and other proliferation pathways will be required to determine the downstream 
mechanisms responsible for the reduction in cell viability caused by mavacoxib in other cell 
types. 
 
To substantiate the previous data, we determined the effect of mavacoxib on colony 
forming ability as an assay of replicative cell death. We showed that mavacoxib treatment 
significantly reduced colony formation in a dose-dependent manner in all cell lines tested 
(Figure 3A-C). The ability of mavacoxib to induce replicative cell death is comparable 
between canine and human bladder TCC cell lines, with a dose-dependent decrease in colony 
forming ability detected across the panel (Figure 3C). The induction of replicative cell death 
by the COX-2 inhibitor mavacoxib supports previous data demonstrating a reduction in cell 
viability with treatment of this drug.  
 
Mavacoxib can induce caspase-dependent apoptosis in canine and human cancer cell 
lines 
 
Cancer cells have the ability to evade apoptosis by deregulating apoptotic pathways, 
allowing damaged cancer cells to grow rapidly to form an aggressive tumour. Here, we 
demonstrate that mavacoxib can induce caspase-dependent apoptosis in all cell lines tested 
when treated at 100 μM or above (Figure 4). A dose-dependent increase in the number of 
apoptotic cells is detected in KTOSA5, U2OS, REM and K9TCC cells (Figure 4A-C and 4E), 
however only the highest dose of mavacoxib produced a statistically significant response in 
LILY (Figure 4D) and T24 cells (Figure 4F). LILY and T24 cells express low levels of COX-
2, however KTOSA5 and U2OS cells also express low levels of COX-2 and these cell lines 
remain more sensitive to mavacoxib induced caspase-dependent apoptosis. Mavacoxib was 










able to reduce cell viability in LILY and T24 cells at lower concentrations, suggesting that 
these cell lines may be inherently resistant to mavacoxib-induced caspase-dependent 
apoptosis, but other apoptotic pathways may be involved. 
 
Cellular migration is inhibited by mavacoxib in a cell-line dependent manner 
 
The ability of mavacoxib to inhibit the migration of human and canine cancer cell 
lines in-vitro was investigated (Figure 5). Either a standard scratch assay (KTOSA5, U2OS, 
REM and LILY cell lines (Figure 5Bi-iv)) or the Ibidi
® 
Culture-Insert migration assay 
(K9TCC and T24 cell lines (Figure 5 Bv-vi)) was used to measure the migration of cancer 
cells incubated with mavacoxib for 24 hours. Here, we demonstrate that mavacoxib reduces 
the migration of human and canine cancer cell lines in-vitro (Figure 5B). The lowest 
concentration of drug to yield a statistically significant result is shown for each cell line, with 
a representative image of the assay conducted in K9TCC cells shown in Figure 5A. The 
canine and human osteosarcoma cell lines (KTOSA5 (Figure 5Bi) and U2OS (Figure 5Bii) 
respectively) respond in a comparable manner, however the human bladder TCC cell line 
(T24) requires a higher concentration of mavacoxib to yield a significant result (Figure 5Bvi) 
compared to the canine bladder TCC cell line (K9TCC) (Figure 5Bv). The inflammatory 
mammary carcinoma cell line LILY required higher doses of mavacoxib and a larger initial 
gap width before a significant response was detected, consistent with this cell line being more 
resistant to mavacoxib (Figure 5Biv). These results indicate that mavacoxib inhibits cell 
migration in cell-line dependent manner. 
 
 












This study highlights a novel use for mavacoxib as a potential anti-cancer agent in 
canine patients. The link between inflammation, COX-2 and cancer is well established; when 
inflammation and oncogenic activation converge, inflammatory transcription factors are 
activated in tumour cells, which produce inflammatory mediators, cytokines and chemokines, 
including COX-2, that recruit and activate inflammatory immune cells. These cytokines 
activate the same key transcription factors in inflammatory cells, tumour cells and stromal 
cells, resulting in a surge of inflammatory mediators giving rise to a cancer related 
inflammatory microenvironment 
59,60
. This smouldering inflammatory environment has many 
tumour promoting effects, including enhancing proliferation and survival, promoting EMT, 
metastasis and invasion, encouraging angiogenesis and lymphangiogenesis, inhibiting the 
adaptive immune response and altering responses to hormones and chemotherapeutic agents 
60,61
. 
This study demonstrates that mavacoxib is able to reduce cancer cell survival and 
induce cell death. To further understand the mechanisms behind this, the activation of ERK 
and Akt were investigated after cell treatment with mavacoxib. We demonstrate a variable 
response in the phosphorylation status of both ERK and Akt after treatment with mavacoxib, 
with phosphorylation increasing with treatment in some cell lines (REM and K9TCC) and 
decreasing in others (CSKOS and U2OS). Generally, it has been shown that the inhibition of 
COX-2 decreases phosphorylation of both ERK and Akt which in turn inhibits proliferation, 
induces apoptosis and results in cancer cell death. However, several studies have also 
demonstrated that inhibition of COX-2 increases the phosphorylation of these molecules and 
incongruously, this increase in phosphorylation was also associated with apoptosis 
24,57,58,62
. 
Various NSAIDs have been shown to induce changes in ERK phosphorylation between 4 and 










24 hours of incubation 
24,62,63
. Yip-Schneider et al (2003) discuss that short term incubation (1 
hour) of pancreatic carcinoma cells with suldinac did not induce changes in phosphorylation 
but 24-hour incubation did, suggesting that long-term rather than transient activation of this 
pathway was occurring. The basal activation level of the ERK and Akt pathways may also 
influence the extent to which cells may respond in this way to NSAIDs 
62
. Therefore, the 
response of each cell line to the ERK / Akt phosphorylation effects of NSAIDs may be time 
and cell type dependent. Future studies should include cell lines with low and high basal 
activation of these pathways incubated with various different NSAIDs for various times in 
order to investigate what causes the active or suppressive response.  
 
Mavacoxib can induce caspase-dependent apoptosis in a number of cell lines tested 
here (Figure 4). This occurs at higher drug concentrations than the reduction in cell viability, 
suggesting at lower concentrations, mavacoxib may induce caspase-independent cell death 
mechanisms. Caspase-independent cell death has been previously characterised, highlighting 
that caspase inhibitors do not prevent cell death through autophagy, necrosis and apoptosis-
like cell death 
64
. Previous studies have noted similar results with NSAIDs in cancer cell 
lines, with caspase-independent and BAX-independent apoptosis suggested as a possible 
explanation 
35,37,65
. We have previously shown that increased Bcl-2 levels after COX-2 
inhibition may be the result of a mitochondrial-independent apoptotic pathway 
35
. Further 
investigation into the mechanisms driving mavacoxib-induced cell death should include 
methods able to detect early stage apoptosis that may be caspase-independent. 
 
The survival rate of patients with metastatic cancer is greatly reduced in comparison to 
those with a primary tumour. COX-2 has been implicated in the process of epithelial to 
mesenchymal transition (EMT), which allows epithelial primary tumour cells to gain invasive 










and metastatic potential by converting to a mesenchymal phenotype with enhanced mobility 
66
. Several studies have established potential for utilizing COX-2 inhibitors to induce 
mesenchymal to epithelial transition (MET), thereby inhibiting migration and invasion of 
cancer cells. In human bladder cancer, the T24 cell line exhibits a strong EMT phenotype 
which can be reversed by the COX-2 inhibitor etodolac 
67
. Che et al. (2017) have 
demonstrated in lung cancer cells that migration and invasion are stimulated via interleukin-6 
(IL-6) upregulation of COX-2/PGE2 
68
, with a similar finding in head and neck squamous cell 
carcinoma 
69
. In this study, we report that mavacoxib can inhibit migration of a panel of 
canine and human cancer cell lines and that this action is cell line dependent. To establish 
whether mavacoxib exerts its anti-migration effects by reversing EMT, future studies should 
determine the expression of E-cadherin in each cell line before and after mavacoxib 
treatment, along with expression of EMT transcription factors and mesenchymal markers.  
 
Interestingly, the LILY cell line migrated faster and was more inherently resistant to 
mavacoxib than the other canine mammary carcinoma cell line tested. The LILY cell line was 
derived from a canine inflammatory mammary carcinoma, a fast growing, highly malignant 
cancer type in which COX-2 has been shown to be overexpressed with increased risk of 
metastasis and lymph node invasion 
70–72
. Here, we suspect an inflammatory response by the 
LILY cell line, whereby the act of scratching a confluent layer of inflammatory mammary 
carcinoma cells with a pipette tip results in an apoptosis induced inflammatory response that 
stimulates cell proliferation and migration. There is increasing evidence that cells undergoing 
apoptosis signal their presence to the surrounding tissues to elicit tissue repair and 
regeneration 
73
. This phenomenon of tissue damage initiating tissue repair has been coined 
the “phoenix rising pathway” 
74
 and a seminal study in bladder cancer has demonstrated 
evidence for the involvement of the COX-2/PGE2 pathway in cancer stem cell (CSC) 










repopulation of residual tumours in response to chemotherapy-induced damages 
75
. Further 
investigation is required to assess apoptotic activity after damage induction in the LILY cell 
line, along with the expression of COX-2 and release of PGE2.  
 
Many NSAIDs and COX-2 selective inhibitors have demonstrated COX-2 independent 
anti-cancer effects. Here, we show that mavacoxib can exert anti-tumourigenic effects on cell 
lines with low COX-2 expression, advocating that mavacoxib may exert some of its anti-
tumour effects in a COX-2 independent manner. Aside from their COX-inhibitory function, 
NSAIDs have a demonstrated a number of properties that make them attractive anti-cancer 







. Potential mechanisms of these non-COX-2 inhibitory actions 
include the inhibition of carbonic anhydrase and polyamines. For example: De Monte et al. 
(2015) discuss the ability of sulphonamide COX-2 selective inhibitors to inhibit several 
carbonic anhydrase isoforms, enzymes which are important in cancer cell survival in hypoxic 
environments 
79
; and indomethacin, a NSAID, has also been shown to increase the catabolism 
of polyamines, regulators of tumour cell proliferation, by upregulating the activity of 
spermidine/spermine-acetyltransferase (SSAT) in human colon cancer cell lines 
80
. 
Interestingly, derivatives of NSAIDs that lack the ability to inhibit the COX enzymes retain 
their anti-tumour activity 
81–83
 and these COX-independent targets have been associated with 
apoptotic, proliferative, angiogenic and metastatic pathways 
81
 but have yet to be fully 
elucidated. An interesting future research avenue would be to confirm the COX-2-dependent 
and COX-2-independent effects of mavacoxib by producing a mavacoxib derivative that 
lacks COX-2 inhibitory action, and to determine whether mavacoxib inhibits the carbonic 
anhydrase or polyamine pathways.  
 










Currently, there are a number of NSAIDs approved for clinical use. With ample 
epidemiological evidence demonstrating an inverse correlation between NSAID use and the 
incidence and progression of cancer, there have been numerous trials attempting to validate 
these drugs for use as cancer therapeutics. Aspirin, celecoxib, ibuprofen and piroxicam have 
all demonstrated positive anti-neoplastic effects during clinical trials 
76,84–90
. However, the 
use of these drugs for cancer prevention and therapy remains controversial. Many clinical 
studies have not indicated a significant benefit to the patient, and in combination with the 
side-effects associated with NSAIDs (which can range from moderate GI toxicity to severe 
cardio toxicity), there is limited enthusiasm for their use 
91
. Given these controversies it is 
unlikely that COX-2 inhibitors in particular will be utilized as a monotherapy for cancer, 
however, they may be effective adjuvants when used in conjunction with other therapeutic 
approaches. For example, dual modality treatments are currently offered for several human 




In the field of veterinary oncology, numerous trials are attempting to elucidate the 
potential of NSAIDs as a cancer treatment for dogs, both as a single treatment and as part of 
dual modality or metronomic chemotherapy treatment options. Piroxicam, a non-selective 
COX inhibitor used in human medicine, has been one of the most widely studied. Piroxicam 
as a single mode treatment has been established as an effective anti-cancer agent in the 
treatment of transitional cell carcinoma of the urinary bladder in dogs, with cases of both 
complete and partial remission noted 
95
. In canine prostatic carcinoma, both piroxicam and 
carprofen (a preferential COX-2 inhibitor; this class of drugs affects both COX-1 and COX-2 
but is more selective towards COX-2) significantly increased survival time as single agents 
when compared to untreated dogs in both early stage and metastatic disease 
96
. As part of 
dual modality treatment and metronomic chemotherapy, piroxicam significantly increased 










survival time and incidences of complete or partial remission compared to the same 
treatments without piroxicam in a range of cancer types 
97
 including invasive urothelial 
carcinoma 
98
 and primary lung carcinoma 
99
. A recent review on canine mammary carcinoma 
concludes that including NSAIDs in treatment significantly improves survival, especially in 
inflammatory mammary carcinomas when NSAIDs are used alone as palliative treatment or 
in combination with chemotherapy 
100
. However, conflicting evidence still remains. Studies 
in transitional cell carcinoma of the urinary bladder, nasal carcinomas and multicentric 
lymphoma utilizing combinations of chemotherapeutics or radiotherapy with piroxicam and 
firocoxib demonstrated no significant difference in progression free and overall survival 
compared to other treatment regimens 
101–103
. A study in mammary carcinoma demonstrated 
that surgery plus adjuvant chemotherapy significantly improved overall survival time 
compared to surgery alone, but there was no significant difference when chemotherapy was 
combined with or without NSAIDs 
104
. COX-2 expression was found to be a significant 
factor in survival time in this study and the author suggests that immunohistochemical score 
of COX-2 should be included as a predictive factor for this cancer type 
104
. Interestingly, 
Knapp et al. (2016) noted that when vinblastine treatment was followed by piroxicam as two 
single agents there was a significant increase in overall survival time compared to dogs 
receiving the same agents simultaneously. It is suggested that this could be the consequence 
of drug resistance developing separately for each drug over time rather than concurrently, 
which raises the interesting possibility that chemotherapy may sensitize the tumour to the 
action of COX inhibitors 
98
. After chemotherapy treatment, resistant cells can go on to 
repopulate the tumour, a process that has been shown to involve the COX-2 pathway 
75
. 
Therefore, chemotherapy may select for a clone of tumour cells with increased COX-2 
activity, rendering them more sensitive to the actions of COX inhibitors. If this occurs, even 










tumours with low COX-2 expression initially may benefit from a treatment program 
consisting of chemotherapy and NSAIDs sequentially.  
 
One of the recurring topics across many of the studies mentioned above is that of 
quality of life, a primary concern when treating veterinary cancer patients. In many cases 
curative treatment is not an option and palliative care is opted for. In the studies mentioned 
above, several factors used to assess quality of life (including appetite, activity levels and 
pain) were all noted to be improved in patients treated with NSAIDs (reported through owner 
questionnaires),  even in cases where NSAIDs showed no improvement in survival time 
compared to other treatment options 
95,99,101,102
. In one study, most owners requested that their 
dogs remain on piroxicam treatment even if tumour remission did not occur, due to their 
subjective improvement in quality of life 
95
. Given the importance of quality of life, this is 
clinically relevant finding and should be taken into consideration when decisions are made 
regarding treatment options in veterinary cancer care. 
 
Currently the use of mavacoxib in the clinic is unorthodox as a result of the long half-
life of the drug potentially resulting in side-effects which are problematic for the patient. The 
usual dosing regimen for mavacoxib comprises of administration at monthly intervals after 
initial doses of 2 mg/kg at day 0 and day 14, maintaining plasma concentrations at a steady 
state of around 0.52 – 1.11 μg/μl (1.35 – 2.88 μM) 
105,106
. Studies have demonstrated that the 
safety profile of mavacoxib is comparable to other veterinary NSAIDs 
107,108
, and suggests 
that the benefits of reduced dosing should be exploited. Although the concentrations of 
mavacoxib utilized in this study are higher than plasma concentrations, there is currently a 
concerted research effort to develop targeted drug delivery systems for cancer therapies 
which would allow increased concentrations of therapeutic agents to target the tumour site 










while minimising undesirable side-effects. These include using nanoparticles to encapsulate 
therapeutic agents and release them in a controlled manner to target diseased cells with 
increased specificity 
109–111
. If the challenges of dosing and toxicity for drugs like mavacoxib 
can be diminished by improved drug delivery systems, their anti-cancer potential may be 
exploited. 
 
In conclusion, we show that mavacoxib is an effective cytotoxic agent on a range of 
tumour types and across species. We highlight that mavacoxib can exert anti-tumour effects 
on cells expressing a low level of COX-2, however further mechanistic studies are required to 
understand the COX-2 dependent and COX-2 independent actions of mavacoxib. Further in 
vivo and preclinical studies will be required to fully elucidate the potential of mavacoxib as 
an anti-cancer agent in conjunction with its clinical benefits as an anti-inflammatory drug.  
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U2OS 0.00 2.44 
KTOSA5 0.24 2.32 
CSKOS 0.00 2.14 
REM 0.51 2.45 
LILY 0.36 2.61 
K9TCC 0.58 5.54 
K9TCC-AXA 0.99 5.44 
K9TCC-In 0.99 5.67 
K9TCC-Sh 0.76 6.17 
T24 0.00 5.23 
5637 0.77 5.83 
HT-1376 0.62 6.14 
 
COX-2 expression was quantified by densitometry relative to 𝛽-actin expression. PGE2 
production was assessed by ELISA using conditioned media from cells incubated for 24 






















































Figure 1. COX-2 expression and PGE2 production of a panel of canine and human cancer 
cell lines. (A) COX-2 expression was assessed for each cell line by western blot analysis. 30 
µg of protein was loaded per well and 𝛽-actin was used as a loading control. (B) Spearman‟s 
nonparametric statistical test was used to assess correlation between COX-2 expression and 
PGE2 production. Spearman‟s correlation (r = 0.7478) determined that COX-2 expression and 
PGE2 production are positively correlated and this correlation is statistically significant 
(p=0.0071 **).  
 
Figure 2. Mavacoxib reduces cell viability in a dose-dependent manner. (A) All cell lines 
were subject to increasing doses of mavacoxib and incubated for 72 hours prior to measuring 
cell viability. Data is shown for two osteosarcoma cell lines (canine CSKOS (i) and human 
U2OS (ii)), one canine mammary carcinoma cell line (REM (iii)) and two bladder TCC cell 
lines (canine K9TCC (iv) and human T24 (v)). Differences were deemed significant with a p-
value of less than 0.05 (p<0.05 *, p<0.01 **, p<0.001 #). (B) Downstream markers of 
proliferation were analysed by western blot analysis after treatment with mavacoxib. Cells 
were subject to increasing doses of mavacoxib for 24 hours prior to harvesting and probed for 
COX-2, ERK, phosphorylated-ERK (p-ERK), Akt and phosphorylated-Akt (p-Akt). 30 µg of 
protein was loaded per well and 𝛽-actin was used as a loading control.  











Figure 3. Mavacoxib induces replicative cell death in a panel of canine and human cancer 
cell lines. The colony forming ability of (A) osteosarcoma cell lines (canine CSKOS and 
KTOSA5 and human U2OS), (B) canine mammary carcinoma cell lines (REM and LILY) 
and (C) bladder TCC cell lines (canine K9TCC, K9TCC-Sh, K9TCC-In, K9TCC-AXA and 
human 5637, T24 and HT-1376) was assessed with increasing doses of mavacoxib. After 14 
days, the number of colonies were counted manually. Differences were deemed significant 
with a p-value of less than 0.05 (p<0.05 *, p<0.01 **, p<0.001 #). 
 










Figure 4. Mavacoxib induces apoptosis in canine and human cancer cell lines. A panel of 
cancer cell lines (canine osteosarcoma KTOSA5 (A), canine mammary REM (C) and LILY 
(D), canine bladder TCC K9TCC (E), human osteosarcoma U2OS (B) and human bladder 
TCC T24 (F)) were subject to increasing doses of mavacoxib and apoptotic activity was 
measured 48 hours after treatment. Differences were deemed significant with a p-value of 
less than 0.05 (p<0.05 *, p<0.01 **, p<0.001 ***). 
 
Figure 5. Mavacoxib inhibits cellular migration in a cell-line dependent manner. (A) 
Representative image is of the Ibidi
® 
migration assay.  Canine bladder TCC K9TCC cells 
were seeded into each well of the insert and treated with mavacoxib. After 24 hours 
incubation, the insert is removed and the gap distance is measured at several time points up to 
48 hours. Six points were measured along the gap and the average distance calculated at each 
time point. (B) A panel of canine osteosarcoma (KTOSA5 (i)), canine mammary (REM (iii) 
and LILY (iv)), canine bladder TCC (K9TCC (v)), human osteosarcoma (U2OS (ii)) and 
human bladder TCC (T24 (vi)) cancer cell lines were treated with mavacoxib and cellular 
migration was assessed. Shown are the lowest doses of mavacoxib able to induce a 










statistically significant response in each cell line. Differences were deemed significant with a 






Supplementary table 1. Panel of canine and human cancer cell lines. The panel of canine 
and human cell lines utilised in this study, highlighting the species and cancer type. Each cell 
line was characterised by cellular morphology and doubling time. 
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